Orion Corporation (pharmaceutical company): Difference between revisions
Content deleted Content added
| Line 35: | Line 35: | ||
:* Eldepryl (''[[selegiline]]'') |
:* Eldepryl (''[[selegiline]]'') |
||
* |
*Animal sedatives ([[sympatholytic]]s) |
||
:* Dexdomitor ([[dexmedetomidine]]'') |
:* Dexdomitor ([[dexmedetomidine]]'') |
||
:* Domitor ([[medetomidine]]'') |
:* Domitor ([[medetomidine]]'') |
||
Revision as of 10:31, 4 May 2020
 | |
Native name | Orion Oyj |
|---|---|
| Company type | Julkinen osakeyhtiö |
| Nasdaq Helsinki: ORNAV,ORNBV | |
| Industry | Pharmaceutical industry |
| Founded | 1917 |
| Headquarters | Espoo, Finland |
Key people | Timo Lappalainen (President and CEO), Hannu Syrjänen (Chairman) |
| Products | Pharmaceuticals, active pharmaceutical ingredients and diagnostic tests |
| Revenue |  €1.074 billion (2016) |
| €315 million (2016) | |
| €249 million (2016) | |
| Total assets | €1.063 billion (2016) |
| Total equity | €641 million (2016) |
Number of employees | 3,446 (2016) |
| Website | www |
| Footnotes / references [1] | |
Orion Corporation (Finnish: Orion Oyj),[2][3] founded in 1917 and headquartered at Espoo, Finland, is a Finnish company, which develops, manufactures and markets pharmaceuticals, active pharmaceutical ingredients and diagnostic tests for global markets. The company also has a large R&D unit in Turku.
Orion's class A and B shares are listed on the Helsinki Stock Exchange.
Products
 |
|
References
- ^ https://www.orion.fi/globalassets/documents/orion-group/investors/annual-reports/orion-financial-statement-documents-2016.pdf
- ^ "Orion Oyj". Business Information System. Finnish Patent and Registration Office and Finnish Tax Administration. Retrieved 22 October 2019.
- ^ "Yhtiöjärjestys" [Corporate by-laws] (in Finnish). Espoo: Orion Oyj. 22 March 2017. Retrieved 22 October 2019.
External links
